Neurowave Medical Technologies (NMT) will launch the OTC version of its popular ReliefBand® Voyager, an innovative and highly efficacious Transdermal Neuromodulation Medical Device used to treat people suffering from Motion Sickness, at the 2013 Cruise Shipping Asia Trade Conference. ReliefBand is the #1 brand trusted by millions of people to relieve their symptoms, allowing them to take control of motion sickness, and travel with confidence.
Motion Sickness affects up to 33% of the population with 7.5% of these sufferers experiencing severe and debilitating symptoms. Motion Sickness is the #1 reason that prevents people from participating and enjoying activities like boating, cruising, plane rides, or traveling.
For many people, medications not only have limited efficacy but can also cause significant side effects. In addition, most of the common medications are contraindicated for use with alcohol or use with motor vehicles thus preventing participants from further enjoying their activities. The ReliefBand® Voyager medical device relieves the suffering from Motion Sickness; without the negative side effects of medications.
The ReliefBand® Voyager is a non-drug treatment that uses NMT’s proprietary transdermal neuromodulation technology platform to positively modulate neural pathways using proprietary programmed electrical pulses to treat Motion Sickness. It is the only solution that is safe and clinically proven to be effective before or after symptoms start. The ReliefBand® Voyager begins working within minutes of activation rather than hours as seen with commonly used medications. The ReliefBand® Voyager provides the added benefit of being controlled by the user; sufferers can simply turn the device on/off as needed and get immediate relief. Now everyone has the power to take control of their symptoms without worrying about the negative side effects, or limitations associated with medications.
In a clinical study performed to test the effectiveness of the ReliefBand® for passengers suffering from Motion Sickness during a cruise, results showed a significant reduction in the severity of Motion Sickness over the course of the cruise. Also, the passengers’ ability to eat, drink, and participate in activities went from 14% to 83% after using the ReliefBand®. By the end of the cruise, over 90% of the passengers who received a ReliefBand® were using it continuously, resulting in increased passenger satisfaction and increased spending by these passengers while on cruise.
“ReliefBand® is a recognized and trusted brand in the treatment of motion sickness,” said Farhan Hussain, CEO of Neurowave Medical Technologies. “As the only FDA cleared transdermal neuromodulation medical device in the market, people no longer have to take medications or limit their activities out of fear of when motion sickness may affect them. ReliefBand® allows motion sickness sufferers to take control and to get the relief they need when they need it most, and without the side effects of medications. Up to this point, many people suffering from motion sickness simply avoid travel or any activities that cause symptoms. When they do travel, they have had to take numerous pills in anticipation of when they think they may get sick or before they board a plane/boat/train or car. With ReliefBand® and its fast onset of relief, people can relieve symptoms only when they need it, thus eliminating the need to premedicate or overmedicate.” The ReliefBand® Voyager is available as an over-the-counter medical device through Neurowave Medical Technologies or one of its distributors.
Neurowave Medical Technologies (NMT) will launch the OTC version of its popular ReliefBand® Voyager, an innovative and highly efficacious Transdermal Neuromodulation Medical Device used to treat people suffering from Motion Sickness, at the 2013 Cruise Shipping Asia Trade Conference.